BUZZ-Jefferies sees decline in earnings/share of Australia's CSL

Reuters03-26

** Analysts at Jefferies are of the view that CSL Vifor will be impacted by Viatris possibly launching a generic Venofer (iron sucrose injection) in the U.S. market in second half of CY24

** Brokerage maintains CSL's price target of A$338.50/shr and "buy" rating

** Jefferies expects CSL Vifor to receive a lower distributor margin on sales of the active pharmaceutical ingredient for Venofer in the U.S. compared to the margin on sales of the product in the European Union

** Brokerage sees CSL's earnings per share declining by 0.8% in FY26

** 11 of 16 analysts rate the stock "buy" or higher, 4 "hold" and 1 rates "sell"; their median PT is A$310.00 – LSEG data

** Stock had fallen 1% this year, as of last close

(Reporting by Shivangi Lahiri in Bengaluru)

((shivangi.lahiri@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment